Gene therapy for wet age-related macular degeneration (nAMD)
Part of Eyes & vision clinical trials.
This trial tests a gene therapy (KH658) as a one-time treatment for wet macular degeneration. It's for people whose condition has been stabilized with anti-VEGF injections, and aims to see if it is safe and can reduce the need for frequent eye injections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with wet age-related macular degeneration (nAMD).
- You are between 50 and 85 years old.
- You have already received at least 2 anti-VEGF injections (eye shots to stop bleeding) in the past 6 months and they worked for you.
- Your vision in the treated eye must be between 20/25 and 20/400 on an eye chart.
- You are at least 1 year past menopause if you are a woman.
- You do not have other eye diseases like a torn retina or diabetic retinopathy in the study eye.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy drug (KH631) to see if it is safe and tolerated in people with neovascular age-related macular degeneration (nAMD). It may help your retina problems, but the early goal is mainly to learn about side effects and how the treatment behaves in the eye.
This trial tests a one-time gene therapy injection under the retina for people with wet age-related macular degeneration (AMD), which causes blurry vision from abnormal blood vessels. It aims to reduce the need for frequent eye injections by delivering a treatment that may help the eye produce its own medicine.
This trial tests a new gene therapy called RRG001 for people with the 'wet' form of age-related macular degeneration. It aims to treat leaky blood vessels in the eye that can cause vision loss, possibly reducing the need for frequent eye injections.
This trial tests a new gene therapy, FT-003, for people with wet AMD. It aims to see if a single treatment can help stop vision loss and may reduce the need for frequent eye injections.
This trial tests a new CRISPR-based gene therapy injected into the eye to treat wet age-related macular degeneration (AMD). It aims to stop the growth of abnormal blood vessels that damage your vision.
This trial tests a one-time gene therapy injection (4D-150) for wet AMD. It might help reduce the need for frequent anti-VEGF eye injections by targeting the underlying cause of new blood vessel growth.
Hear when a new Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.